GLP‑1s reshaping wardrobes

A drug sold for blood sugar and weight is now showing up in clothing racks. In March 2026, ThredUp said purchases of large, extra large, and plus-size apparel rose year over year while small and medium sizes fell, a pattern the resale company tied to shoppers cycling through sizes instead of landing in one new closet all at once. (cnbc.com) The medicines behind it are glucagon-like peptide-1 drugs, including Wegovy, Ozempic, and Zepbound. A November 2025 KFF poll found about 1 in 8 U.S. adults, or 12%, said they were currently taking one of these drugs, which is enough people to move demand in ordinary consumer categories like shirts, jeans, and bras. (kff.org) Retailers are not guessing anymore. Circana said U.S. household use of glucagon-like peptide-1 medications reached 23% as of September 2025, up 4 percentage points from 2024, and 80% of users said they expected to need new clothing because their size was changing. (circana.com) That wardrobe turnover is already showing up in receipts. Circana found 55% of active glucagon-like peptide-1 users had already bought new clothing or footwear, and about 25% said they were updating their wardrobes not just for fit but to refresh how they looked. (circana.com) The first clues are coming from categories where fit changes fast. Circana said larger bra band sizes of 42 and up and D cups were losing share, while band size 40 and B and C cups were gaining, which gives apparel companies an early read on bodies moving before the rest of the closet catches up. (circana.com) Stitch Fix says customers are spelling this out in their orders. Chief executive Matt Baer said on the company’s March 11, 2026 earnings call that more clients were mentioning weight loss as a reason they needed new sizes, which is useful for a business built around sending boxes of clothes to people in transition moments. (fool.com) ThredUp is seeing the same change from the other side of the closet. Chief executive James Reinhart said on the company’s March 2, 2026 earnings call that glucagon-like peptide-1 users were cleaning out wardrobes and buying replacement pieces, which fits resale especially well because people often sell clothes that are too big before they finish buying everything new. (fool.com) Wall Street is now trying to put a dollar figure on the closet reset. Bernstein estimated glucagon-like peptide-1 drugs could add as much as $13 billion a year to apparel spending, with off-price chains like T.J. Maxx, discounters like Walmart and Target, and services like Stitch Fix and Rent the Runway among the likely winners. (cnbc.com) The timing is not accidental. CNBC reported that pill versions have started widening access, with Novo Nordisk launching a Wegovy pill in January 2026 and more than 600,000 prescriptions written by February, while Eli Lilly began shipping its Foundayo pill this week through its direct platform. (cnbc.com) So the fashion story is no longer only about trends, colors, or hemlines. It is also about millions of Americans changing size over months instead of years, then replacing five ordinary things at a time: jeans, bras, T-shirts, sneakers, and the clothes that finally fit the body they have now. (circana.com)